VLA15
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lyme Disease
Conditions
Lyme Disease
Trial Timeline
Dec 12, 2022 → Jul 21, 2025
NCT ID
NCT05634811About VLA15
VLA15 is a phase 3 stage product being developed by Pfizer for Lyme Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05634811. Target conditions include Lyme Disease.
What happened to similar drugs?
0 of 2 similar drugs in Lyme Disease were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05634811 | Phase 3 | Completed |
| NCT05477524 | Phase 3 | Active |
Competing Products
8 competing products in Lyme Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1975 | Moderna | Phase 2 | 0 |
| VLA15 with Alum + VLA15 without Alum | Pfizer | Phase 1 | 29 |
| VLA15 + Placebo | Pfizer | Phase 2 | 35 |
| VLA15 + Placebo | Pfizer | Phase 3 | 47 |
| VLA15 + Placebo | Pfizer | Phase 2 | 35 |
| VLA15 | Pfizer | Phase 3 | 44 |
| VLA15 + Placebo | Pfizer | Phase 2 | 35 |
| Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine | Baxter | Phase 1/2 | 29 |